Cargando…

Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines

Hyaluronan (HA) is the main glycosaminoglycan of the extracellular matrix. CD44 is the most important HA receptor, and both have been associated with poor prognosis in cancer. Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively activated tyrosine kinase (Breakpoint Cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lompardía, Silvina, Díaz, Mariángeles, Pibuel, Matías, Papademetrio, Daniela, Poodts, Daniela, Mihalez, Cintia, Álvarez, Élida, Hajos, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662747/ https://www.ncbi.nlm.nih.gov/pubmed/31358779 http://dx.doi.org/10.1038/s41598-019-47248-8

Ejemplares similares

Author Correction: Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines
por: Lompardía, Silvina, et al.
Publicado: (2020)

The scrambled story between hyaluronan and glioblastoma
por: Pibuel, Matías Arturo, et al.
Publicado: (2021)

Antitumor effect of 4MU on glioblastoma cells is mediated by senescence induction and CD44, RHAMM and p-ERK modulation
por: Pibuel, Matías Arturo, et al.
Publicado: (2021)

Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling
por: Ledesma, Martín, et al.
Publicado: (2023)

4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells
por: Pibuel, Matías A., et al.
Publicado: (2023)

Autophagy-Mediated Exosomes as Immunomodulators of Natural Killer Cells in Pancreatic Cancer Microenvironment
por: Papademetrio, Daniela L., et al.
Publicado: (2021)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
por: Kumar, Rahul, et al.
Publicado: (2020)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest
por: Drullion, Claire, et al.
Publicado: (2012)

Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment
por: Kaweme, Natasha Mupeta, et al.
Publicado: (2021)

Acute Promyelocytic Leukemia or Acute Myeloid Leukemia with Mutated NPM1?
por: Cloobs-Venezia, Maximiliano, et al.
Publicado: (2022)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia
por: Krakowsky, Rosanna H. E., et al.
Publicado: (2018)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
por: Tavil, Betül, et al.
Publicado: (2013)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
por: Angriman, Federico, et al.
Publicado: (2015)

Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female
por: Agrawal, Prabhat, et al.
Publicado: (2015)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia
por: Balasubramanian, Pradeep, et al.
Publicado: (2015)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia
por: Pandey, Neetu, et al.
Publicado: (2019)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients
por: Ammar, Mariam, et al.
Publicado: (2020)

Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
por: Chen, Xiaowen, et al.
Publicado: (2020)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f98v3m59621q0pjr982m6lcrou